Discovery of key protein behind cancer relapse and progression can lead to new therapies

Cancer cases have been rising over the years and according to the statistics, the number of people living with cancer will continue to increase. Despite decades of research, cancer treatments are still inefficient and have unacceptable side effects that continue to prompt an urgent need for new approaches to prevention and treatment. Uncovering novel mechanisms associated with cancer would fill current knowledge gaps and help meet this need.


"We discovered a mechanism involving MBNL1 protein that predicts several characteristics of cancer such as progression and relapse," said Dr Debleena Ray, Senior Research Fellow at Duke-NUS Cancer and Stem Cell Biology (CSCB) programme, the lead author of this study. "We found that MBNL1 protein is present in low amounts in many of the common cancers in the world, including breast, colorectal, stomach, lung and prostate cancers, which when combined account for about 49 per cent of all cancers diagnosed in 2018. This can cause poor overall survival in many of these commonly-occurring cancers."

The team also found that this mechanism can be reversed by blocking the JNK protein, a well-known target in cancer treatment, in cancer cells with low levels of MBNL1.

"While JNK inhibitors have been tested as a cancer drug previously, currently there are no clinical trials for the same. However, if in the future there is a JNK inhibitor against cancer, MBNL1 could be used as a biomarker to select patients for the treatment," said Adjunct Associate Professor David Epstein at the Duke-NUS CSCB programme and the co-corresponding author of this study.

"Cancer is a global health challenge and Singapore is no exception. This study provides important information about novel targets and biomarkers that are implicated in several major cancers, which could lead to the development of new treatment strategies that can improve the lives of patients," said Prof Patrick Casey, Senior Vice Dean for Research at Duke-NUS.

Over the next year, the team will be investigating the role of MBNL1 in colorectal cancer and exploring the potential of anti-JNK therapeutic for cancer using antisense technology, a tool that is used for the inhibition of gene expression.

Materials provided by Duke-NUS Medical School . Note: Content may be edited for style and length.

Duke-NUS Medical School. "Discovery of key protein behind cancer relapse and progression can lead to new therapies." ScienceDaily. ScienceDaily, 30 June 2020. .

Duke-NUS Medical School. "Discovery of key protein behind cancer relapse and progression can lead to new therapies." ScienceDaily. (accessed June 30, 2020).



Feb. 5, 2020 — Causes of cancer are being catalogued by a huge international study revealing the genetic fingerprints of DNA-damaging processes that drive cancer development. This detailed list of genetic ...

Apr. 17, 2017 — Scientists have unlocked an important mechanism that allows chemotherapy-carrying nanoparticles—extremely small objects between 1 and 100 nanometers (a billionth of a meter)—to directly access ...

May 23, 2016 — While breast cancer is the most common cause of cancer death in women worldwide, ovarian cancer also is a significant source of mortality as the fifth leading cause of cancer death among women. These ...

Oct. 5, 2015 — Genetic polymorphisms associated with cancer progression lead to variations in gene expression and may serve as prognostic markers for lung cancer, researchers show. They found that in patients with ...
News Topics :
Now, a new study from National University of Singapore NUS researchers has demonstrated a potential method for treating advanced liver cancers like HCC. Led by Associate Professor Edward Chow, who...
A new study led by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute OSUCCC James reveals...
Does sugar directly feed cancers, boosting their growth The answer seems to be Yes at least in mice according to a study led by researchers at Baylor College...
Dengue virus DENV infects about 400 million people annually around the world, with a high prevalence in tropical and sub tropical regions. The virus causes diseases ranging from mild dengue fever...
Scientists have revealed close up details of a vital molecule involved in the mix and match of genetic information within cells opening up the potential to target proteins of this...